The Latest
-
Illustration: Deena So Oteh for Industry Dive/PharmaVoice
The 2023 PharmaVoice 100
This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.
-
Permission granted by Phil Inc
Sponsored by Phil IncOptimizing your hub services program with a gross-to-net lens
In today’s Biopharma landscape, considering Gross-to-Net is essential for effectively designing and optimizing patient support programs.
-
iStock via Getty Images
Endangered horseshoe crabs could lead the charge in pharma’s animal-free future
An effort to spare the species from blood collection is one of many ways the industry is turning away from animals for R&D.
-
iStock via Getty Images
Moderna’s bold five-year plan reflects Big Pharma tradition of ‘Will they deliver?’
Forecasts from the biggest pharma companies follow a pattern of thinking big and manifesting the desired outcome.
-
Courtesy of Sanofi
O.G. Ice-T teams up with Sanofi in horror-themed flu vax ad
The French pharma’s latest vaccine campaign aims to raise awareness about the flu’s complications for marginalized groups.
-
saengsuriya13 via Getty Images
Q&AIn the renal space, innovation could tackle health disparities. But the system doesn’t reward it.
Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.
-
Stock via Getty Images
Catching up with 2022 PharmaVoice 100 honorees
Tapping into our growing community for expertise and inspiration.
-
Stock via Getty Images
A healthcare paradox: Drugs are too expensive but ‘easy’ to afford, Americans say
A new poll shows that Americans generally support several key IRA provisions, including Medicare price negotiations.
-
Permission granted by Regeneron
A tale of two biotechs — 2seventy, Regeneron announce C-suite shakeups
The biotech’s chief financial officer Robert Landry is retiring in February.
-
Igor Kutyaev via Getty Images
Ex-Sanofi executive Sibold joins Madrigal as new CEO
Bill Sibold has led Sanofi's specialty care business unit for the past six years. He replaces Paul Friedman as head of the NASH drug developer.
-
Stock via Getty Images
Biotech SpotlightImmuneering takes aim at cancer’s ‘superhighway’
After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.
-
Stock via Getty Images
In advocates’ ongoing push for superbug funding, ‘$6 billion is nothing’
The PASTEUR Act is likely heading for another legislative blow, but advocates say they see a future for the mechanism to fund the battle against antimicrobial resistance.
-
Permission granted by Armon Sharei
Profile‘Not all rainbows and unicorns’ — a former CEO dishes on his rocky biotech ride
Armon Sharei took his startup SQZ from a graduate project at MIT to a Big Pharma partnership worth $1B+. Despite the company’s stumbles, Sharei’s enthusiasm for biotech’s future remains.
-
Stock via Getty Images
Pharma faces a slew of leadership shakeups
Biogen, Sanofi, Bristol Myers Squibb and more have all recently announced major executive changes.
-
Courtesy of Empress Therapeutics
ProfileWhy this scientist left Janssen to help ‘revolutionize’ small molecule drug discovery
Murray McKinnon, CSO of Empress Therapeutics, believes its drug discovery platform holds the key to treating and detecting many diseases.
-
Courtesy of Roche
Hope sputters for emerging anti-TIGIT drug class
Leaked data for Roche’s immunotherapy appeared positive, but some experts aren’t convinced it’ll make an impact for cancer patients.
-
Permission granted by Mike Zapolin
A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen?
Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery route holds promise for far more drugs.
-
Permission granted by Roz Brewer
Roz Brewer announces sudden departure as CEO of Walgreens
The exec who set out to overhaul the long-time pharmacy giant offered few details on why she's stepping down.
-
Bill Oxford via Getty Images
Lawmakers are already gunning for more dramatic drug pricing reforms
Medicare just announced its first-ever drug price negotiations and legislators are quickly pushing to broaden the program.
-
Permission granted by CSL Seqirus
Finding the right flu vaccine is hard. Getting people to take it is harder.
Experts have determined the strains of this year’s flu season — now the question is whether people are too fatigued by the pandemic to be immunized.
-
Win McNamee / Staff via Getty Images
Medicare named the first 10 drugs up for negotiation. Now what?
The list of blockbuster cardiovascular, diabetes and cancer drugs gives the industry a window into how regulators are approaching price negotiations.
-
Stock via Getty Images
5 of the best places to work in pharma, according to employees
Work-life balance is one major common denominator among the top-ranked pharma employers on Glassdoor.
-
iStock via Getty Images
Q&A // Biotech Spotlight‘We need to do better:’ A biotech CEO on standing apart from the crowd
The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.
-
Stock via Getty Images
Why pharma isn’t done tackling migraines
In the high-growth but competitive field of migraine treatments, CGRP drugs have changed the game — but the search is still on for more options.
-
Stock via Getty Images
Are weight loss drugs a win for the global economy?
As Novo Nordisk’s drug Wegovy sways Denmark’s economy, we're examining wider implications for the weight loss market.
-
Stock via Getty Images
Drug shortages: The ‘fundamental problem’ that has pharma’s top regulator ‘fired up’
FDA Commissioner Robert Califf suggested larger reforms are needed to bolster the generic drug industry and prevent future medication shortages.
